Drug intelligence / Profile preview

Aladrine

Development stage: Unknown
Lead developer: Waterley Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Aladrine is a small molecule hepatoprotective agent containing malopidine hydrochloride (also known as malotilate). Marketed by Waterley Pharmaceuticals, it is indicated for the treatment of various hepatology-related conditions, including chronic liver disease and liver cirrhosis. The drug functions as a hepatotrophic agent by stimulating the synthesis of RNA and proteins within hepatocytes, which facilitates liver regeneration and improves metabolic function. By promoting the recovery of impaired liver cells and stabilizing cell membranes, Aladrine helps to improve clinical outcomes and liver function parameters in patients with chronic hepatic disorders.

Brand names: Aladrine
Other names: malopidine hydrochloridemalotilate

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Aladrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aladrine.

Explore the full profile